Osteoporosis Therapeutics Market
Osteoporosis Therapeutics Market Analysis by Drug Class (Bisphosphonates, Selective Estrogen Inhibitor Modulators (SERM), Parathyroid Hormone Therapies), by Route of Administration (Oral, Injectable), by Region - Global Forecast 2022-2026
Analysis of Osteoporosis Therapeutics market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Market Outlook of Osteoporosis Therapeutics
The global osteoporosis therapeutics market stands at a valuation of US$ 12.7 Bn currently, and is predicted to reach US$ 14.2 Bn by the end of 2026.
Consumption of osteoporosis therapeutic drugs is anticipated to increase at a CAGR of 2.9% from 2022 to 2026.
Report Attributes |
Details |
|
Osteoporosis Therapeutics Market Size (2022) |
US$ 12.7 Bn |
|
Projected Year Value (2026F) |
US$ 14.2 Bn |
|
Global Market Growth Rate (2022-2026) |
2.9% CAGR |
|
United States Market Share (2022) |
41% |
|
Key Companies Profiled |
|
Demand for osteoporosis therapeutics in China is expected to progress at a higher than global average CAGR of 5.4% through 2026. Poor lifestyle choices and rising aging population have majorly influenced demand for osteoporosis treatment on a global scale.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Osteoporosis Therapeutics Demand Analysis (2017-2021) in Comparison to Market Growth Forecasts (2022-2026)
Incidence of osteoporosis has witnessed an exponential rise over the past few years and this trend is expected to be prevalent over the coming years as well. Osteoporosis is still one of the major diseases that go undiagnosed and untreated due to a lack of awareness about the condition.
Increasing geriatric population, rising awareness for osteoporosis, increasing availability of diagnostic procedures, growing sedentary lifestyle, and rapid development of novel treatments are major factors that guide the osteoporosis therapeutics market growth through 2026.
Longer time taken by regulatory bodies for approval of new osteoporosis drugs and side effects associated with prolonged use of the same are expected to have a restraining effect on the global osteoporosis therapeutics market potential.
Sales of osteoporosis drugs are projected to rise at a sluggish CAGR of 2.9% from 2022 to 2026.
What Will Favor Demand for Osteoporosis Drugs Going Ahead?
“Surging Aging Population to Boost Consumption of Osteoporosis Therapeutic Drugs”
The world is witnessing a significant rise in its aging population and this has shaped the healthcare industry with new opportunities. Osteoporosis is very common in the geriatric population and hence as the aging population increases, it drives a caseload of osteoporosis as well.
China and the United States are two prominent markets where the geriatric population is increasing and hence will be rewarding markets for osteoporosis drug vendors.
How is Osteoporosis Therapeutics Market Growth Being Hindered?
“Long Approval Times by Regulatory Authorities to Dent Osteoporosis Drug Sales”
All drugs have to undergo an approval procedure by respective regulatory authorities of their regions in order to be commercialized and available for patients and healthcare professionals.
The time taken for approval by these authorities for osteoporosis drugs is long and hence delays entry into the market and slows down osteoporosis therapeutics market potential.
“Lack of Awareness & Proper Diagnosis to Hinder Market Expansion”
General awareness about osteoporosis is very low compared to other prevalent diseases and this has hampered osteoporosis therapeutics market potential in the past and is expected to follow a similar trend over the forecast period as well.
Furthermore, the lack of diagnostic equipment for osteoporosis is also expected to constrain osteoporosis therapeutics market growth throughout the forecast period.
Which Regional Markets Should Osteoporosis Therapeutic Drug Suppliers Focus On?
“North America Expected to Account for Highest Osteoporosis Therapeutics Demand”
The North America osteoporosis therapeutics market is anticipated to have a bright outlook over the coming years and will hold a dominant market share in the global landscape.
Increasing sedentary lifestyles, rising instances of osteoporosis, the presence of developed healthcare infrastructure, and high healthcare spending potential are expected to be major factors influencing shipments of osteoporosis drugs through 2026.
The Europe osteoporosis therapeutics market is expected to hold a significant market share in the global landscape throughout the forecast period. Increasing spending on research and development activities are expected to prominently influence osteoporosis therapeutics market potential in this region.
South Asia and East Asia are predicted to provide lucrative opportunities for osteoporosis therapeutics market players. Rising awareness of osteoporosis, increasing healthcare expenditure, and the growing aging population in the aforementioned regions are expected to majorly influence osteoporosis therapeutics market growth.
Malaysia, India, and China are anticipated to be rewarding markets for osteoporosis drug suppliers.
Country-wise Insights
Why Should Osteoporosis Drug Manufacturers Focus on the U.S.?
“Increasing Incidence of Osteoporosis & High Healthcare Spending Provide Attractive Opportunities”
The U.S. is a highly lucrative market for healthcare products and technologies due to the presence of developed healthcare infrastructure in the nation. The nation has witnessed an increase in the aging population and this is a prominent factor that influences osteoporosis treatment demand in the U.S.
The U.S. accounts for a substantial market share of 41% in the global osteoporosis therapeutics industry landscape.
Will Osteoporosis Drug Suppliers Benefit in China?
“Surging Geriatric Population to Majorly Boost Consumption of Osteoporosis Drugs”
China has witnessed a noteworthy increase in the geriatric population and this will majorly guide osteoporosis drug shipments throughout the forecast period. Increasing healthcare expenditure and rising awareness about osteoporosis are expected to be other trends sculpting osteoporosis therapeutics market growth.
Osteoporosis therapeutic drug consumption is projected to rise at a CAGR of 5.4% from 2022 to 2026 in China.
Category-wise Insights
Which Route of Administration of Osteoporosis Drug Will Hold Major Market Share?
“Oral Route of Administration to Remain Most Popular”
Of the two major routes of administration, the oral segment is anticipated to account for a major market share in the global osteoporosis therapeutics landscape. This can be attributed to the high availability of oral osteoporosis drugs across the world.
However, the injectables segment is projected to see fast growth in sales over the next few years as demand for rapid action drugs increases on a global scale.
How Did the Osteoporosis Therapeutics Market Perform in 2020?
The world witnessed a pandemic of epic proportions in 2020 with the unprecedented outbreak of coronavirus infections and this led to major changes in the world economy. To contain the spread of coronavirus infections, multiple nations implemented total lockdowns and this led to the toppling of various markets.
Change of focus in the healthcare industry due to the pandemic led to a downfall in the osteoporosis therapeutics market growth as well. Lack of healthcare resources and lack of attention to the disease were two major factors slowing down the osteoporosis therapeutics market in 2020. Lack of diagnosis and closure of multiple sales channels also had a negative impact on the osteoporosis therapeutics market.
Osteoporosis drug sales are projected to see slow growth in the post-pandemic era and are anticipated to pick up pace as awareness of osteoporosis increases across the world. Increased focus on preventive healthcare in the post-pandemic world will also drive demand for osteoporosis prevention therapeutics.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Competitive Landscape
Osteoporosis drug manufacturers are increasing their investments in the research and development of novel drugs to fast-track new launches. Osteoporosis treatment injections are gaining popularity and market players are trying to launch these to advance their revenue potential in the global market.
- In October 2021, Entera Bio, a leading biotechnology company, posted crucial data for its oral osteoporosis drug formulation trial that is in its mid-stage. The company moved ahead to phase 3 registration of this study.
Key Segments Covered in Osteoporosis Therapeutics Industry Research
-
by Drug Class :
- Bisphosphonates
- Selective Estrogen Inhibitor Modulators (SERM)
- Parathyroid Hormone Therapies
- Calcitonin
- Rank Ligand Inhibitors
-
by Route of Administration :
- Oral Osteoporosis Therapeutics
- Injectable Osteoporosis Therapeutics
- Other Routes of Administration
-
by Region :
- North America
- Latin America
- Europe
- East Asia
- South Asia & Oceania
- MEA
Table of Content
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions/Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product modifications /Innovation 4. Key Success Factors 4.1. Strategic Developments 4.2. Key Regulations 4.3. Product USPs /Technology 4.4. List of Manufacturers and Providers 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP outlook 5.1.2. Increasing R&D Expenditure 5.2. Forecast Factors - Relevance & Impact 5.2.1. New Product Launches 5.2.2. Cost of Products 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID19 Crisis Analysis 6.1.1. Current COVID19 Statistics and Probable Future Impact 6.1.2. Current GDP Projection and Probable Impact 6.1.3. Current Economic Projection as Compared to 2008 Economic Analysis 6.1.4. COVID19 and Impact Analysis 6.1.4.1. Revenue By Drug Class 6.1.4.2. Revenue By Route of Administration 6.1.4.3. Revenue By Country 6.1.5. 2021 Market Scenario 6.1.6. Quarter by Quarter Forecast 6.1.7. Projected Recovery Quarter 7. Global Osteoporosis Therapeutics Market Volume (Units) Analysis 2017-2021 and Forecast, 2022-2026 7.1. Historical Market Volume (Units) Analysis, 2017-2021 7.2. Current and Future Market Volume (Units) Projections, 2022-2026 7.2.1. Y-o-Y Growth Trend Analysis 8. Global Osteoporosis Therapeutics Market - Pricing Analysis 8.1. Regional Pricing Analysis By Drug Class 8.2. Pricing Break-up 8.2.1. Manufacturer Level Pricing 8.2.2. Distributor Level Pricing 8.3. Global Average Pricing Analysis Benchmark 9. Global Osteoporosis Therapeutics Market Value Analysis 2017–2021 and Forecast, 2022-2026 9.1. Historical Market Value (US$ Mn) Analysis, 2017–2021 9.2. Current and Future Market Value (US$ Mn) Projections, 2022-2026 9.2.1. Y-o-Y Growth Trend Analysis 9.2.2. Absolute $ Opportunity Analysis 10. Global Osteoporosis Therapeutics Market Analysis 2017–2021 and Forecast 2022-2026, by Drug Class 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Mn) Analysis By Products & Services, 2017–2021 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Class, 2022-2026 10.3.1. Bisphosphonates 10.3.2. Selective Estrogen Inhibitor Modulators (SERM) 10.3.3. Parathyroid Hormone Therapies 10.3.4. Calcitonin 10.3.5. Rank Ligand Inhibitors 10.4. Market Attractiveness Analysis By Drug Class 11. Global Osteoporosis Therapeutics Market Analysis 2017–2021 and Forecast 2022-2026, by Route of Administration 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Mn) Analysis By Route of Administration , 2017–2021 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration , 2022-2026 11.3.1. Oral 11.3.2. Injectables 11.3.3. Other Routes of Administration 11.4. Market Attractiveness Analysis By Route of Administration 12. Global Osteoporosis Therapeutics Market Analysis 2017–2021 and Forecast 2022-2026, by Region 12.1. Introduction 12.2. Historical Market Size (US$ Mn) Analysis By Region, 2017–2021 12.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2022-2026 12.3.1. North America 12.3.2. Latin America 12.3.3. Europe 12.3.4. East Asia 12.3.5. South Asia 12.3.6. Oceania 12.3.7. Middle East and Africa (MEA) 12.4. Market Attractiveness Analysis By Region 13. North America Osteoporosis Therapeutics Market Analysis 2017–2021 and Forecast 2022-2026 13.1. Introduction 13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2021 13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2026 13.3.1. By Country 13.3.1.1. U.S. 13.3.1.2. Canada 13.3.2. By Drug Class 13.3.3. By Route of Administration 13.4. Market Attractiveness Analysis 13.5. Key Market Participants - Intensity Mapping 13.6. Drivers and Restraints - Impact Analysis 14. Latin America Osteoporosis Therapeutics Market Analysis 2017–2021 and Forecast 2022-2026 14.1. Introduction 14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2021 14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2026 14.3.1. By Country 14.3.1.1. Brazil 14.3.1.2. Mexico 14.3.1.3. Argentina 14.3.1.4. Rest of Latin America 14.3.2. By Drug Class 14.3.3. By Route of Administration 14.4. Market Attractiveness Analysis 14.5. Key Market Participants - Intensity Mapping 14.6. Drivers and Restraints - Impact Analysis 15. Europe Osteoporosis Therapeutics Market Analysis 2017–2021 and Forecast 2022-2026 15.1. Introduction 15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2021 15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2026 15.3.1. By Country 15.3.1.1. Germany 15.3.1.2. Italy 15.3.1.3. France 15.3.1.4. U.K. 15.3.1.5. Spain 15.3.1.6. Russia 15.3.1.7. Rest of Europe 15.3.2. By Drug Class 15.3.3. By Route of Administration 15.4. Market Attractiveness Analysis 15.5. Key Market Participants - Intensity Mapping 15.6. Drivers and Restraints - Impact Analysis 16. South Asia Osteoporosis Therapeutics Market Analysis 2017–2021 and Forecast 2022-2026 16.1. Introduction 16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2021 16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2026 16.3.1. By Country 16.3.1.1. India 16.3.1.2. Thailand 16.3.1.3. Indonesia 16.3.1.4. Malaysia 16.3.1.5. Rest of South Asia 16.3.2. By Drug Class 16.3.3. By Route of Administration 16.4. Market Attractiveness Analysis 16.5. Key Market Participants - Intensity Mapping 16.6. Drivers and Restraints - Impact Analysis 17. East Asia Osteoporosis Therapeutics Market Analysis 2017–2021 and Forecast 2022-2026 17.1. Introduction 17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2021 17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2026 17.3.1. By Country 17.3.1.1. China 17.3.1.2. Japan 17.3.1.3. South Korea 17.3.1.4. Rest of East Asia 17.3.2. By Drug Class 17.3.3. By Route of Administration 17.4. Market Attractiveness Analysis 17.5. Key Market Participants - Intensity Mapping 17.6. Drivers and Restraints - Impact Analysis 18. Oceania Osteoporosis Therapeutics Market Analysis 2017–2021 and Forecast 2022-2026 18.1. Introduction 18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2021 18.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2026 18.3.1. By Country 18.3.1.1. Australia 18.3.1.2. New Zealand 18.3.2. By Drug Class 18.3.3. By Route of Administration 18.4. Market Attractiveness Analysis 18.5. Key Market Participants - Intensity Mapping 18.6. Drivers and Restraints - Impact Analysis 19. Middle East and Africa Osteoporosis Therapeutics Market Analysis 2017–2021 and Forecast 2022-2026 19.1. Introduction 19.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2021 19.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2026 19.3.1. By Country 19.3.1.1. GCC Countries 19.3.1.2. South Africa 19.3.1.3. Rest of Middle East and Africa 19.3.2. By Drug Class 19.3.3. By Route of Administration 19.4. Market Attractiveness Analysis 19.5. Drivers and Restraints - Impact Analysis 20. Key and Emerging Countries Osteoporosis Therapeutics Market Analysis 2017–2021 and Forecast 2022-2026 20.1. Introduction 20.1.1. Market Value Proportion Analysis, By Key Countries 20.1.2. Global Vs. Country Growth Comparison 20.2. U.S. Osteoporosis Therapeutics Market Analysis 20.2.1. By Drug Class 20.2.2. By Route of Administration 20.3. Canada Osteoporosis Therapeutics Market Analysis 20.3.1. By Drug Class 20.3.2. By Route of Administration 20.4. Mexico Osteoporosis Therapeutics Market Analysis 20.4.1. By Drug Class 20.4.2. By Route of Administration 20.5. Brazil Osteoporosis Therapeutics Market Analysis 20.5.1. By Drug Class 20.5.2. By Route of Administration 20.6. U.K. Osteoporosis Therapeutics Market Analysis 20.6.1. By Drug Class 20.6.2. By Route of Administration 20.7. Germany Osteoporosis Therapeutics Market Analysis 20.7.1. By Drug Class 20.7.2. By Route of Administration 20.8. France Osteoporosis Therapeutics Market Analysis 20.8.1. By Drug Class 20.8.2. By Route of Administration 20.9. Italy Osteoporosis Therapeutics Market Analysis 20.9.1. By Drug Class 20.9.2. By Route of Administration 20.10. Spain Osteoporosis Therapeutics Market Analysis 20.10.1. By Drug Class 20.10.2. By Route of Administration 20.11. BENELUX Osteoporosis Therapeutics Market Analysis 20.11.1. By Drug Class 20.11.2. By Route of Administration 20.12. Russia Osteoporosis Therapeutics Market Analysis 20.12.1. By Drug Class 20.12.2. By Route of Administration 20.13. China Osteoporosis Therapeutics Market Analysis 20.13.1. By Drug Class 20.13.2. By Route of Administration 20.14. Japan Osteoporosis Therapeutics Market Analysis 20.14.1. By Drug Class 20.14.2. By Route of Administration 20.15. South Korea Osteoporosis Therapeutics Market Analysis 20.15.1. By Drug Class 20.15.2. By Route of Administration 20.16. India Osteoporosis Therapeutics Market Analysis 20.16.1. By Drug Class 20.16.2. By Route of Administration 20.17. ASEAN Osteoporosis Therapeutics Market Analysis 20.17.1. By Drug Class 20.17.2. By Route of Administration 20.18. Australia Osteoporosis Therapeutics Market Analysis 20.18.1. By Drug Class 20.18.2. By Route of Administration 20.19. New Zealand Osteoporosis Therapeutics Market Analysis 20.19.1. By Drug Class 20.19.2. By Route of Administration 20.20. GCC Countries Osteoporosis Therapeutics Market Analysis 20.20.1. By Drug Class 20.20.2. By Route of Administration 20.21. Turkey Osteoporosis Therapeutics Market Analysis 20.21.1. By Drug Class 20.21.2. By Route of Administration 20.22. South Africa Osteoporosis Therapeutics Market Analysis 20.22.1. By Drug Class 20.22.2. By Route of Administration 21. Market Structure Analysis 21.1. Market Analysis by Tier of Companies 21.2. Market Concentration 21.3. Market Share Analysis of Top Players 21.4. Market Presence Analysis 21.4.1. By Regional footprint of Players 21.4.2. Product foot print by Players 21.4.3. Channel Foot Print by Players 22. Competition Analysis 22.1. Competition Dashboard 22.2. Competition Benchmarking 22.3. Competition Deep dive 22.3.1. Allergan Plc. 22.3.1.1. Overview 22.3.1.2. Product Portfolio 22.3.1.3. Profitability by Market Segments (Product/Channel/Region) 22.3.1.4. Sales Footprint 22.3.1.5. Strategy Overview 22.3.1.5.1. Marketing Strategy 22.3.1.5.2. Product Strategy 22.3.1.5.3. Channel Strategy 22.3.2. Amgen Inc. 22.3.2.1. Overview 22.3.2.2. Product Portfolio 22.3.2.3. Profitability by Market Segments (Product/Channel/Region) 22.3.2.4. Sales Footprint 22.3.2.5. Strategy Overview 22.3.2.5.1. Marketing Strategy 22.3.2.5.2. Product Strategy 22.3.2.5.3. Channel Strategy 22.3.3. Chugai Pharmaceutical 22.3.3.1. Overview 22.3.3.2. Product Portfolio 22.3.3.3. Profitability by Market Segments (Product/Channel/Region) 22.3.3.4. Sales Footprint 22.3.3.5. Strategy Overview 22.3.3.5.1. Marketing Strategy 22.3.3.5.2. Product Strategy 22.3.3.5.3. Channel Strategy 22.3.4. Daiichi Sankyo Co. Ltd. 22.3.4.1. Overview 22.3.4.2. Product Portfolio 22.3.4.3. Profitability by Market Segments (Product/Channel/Region) 22.3.4.4. Sales Footprint 22.3.4.5. Strategy Overview 22.3.4.5.1. Marketing Strategy 22.3.4.5.2. Product Strategy 22.3.4.5.3. Channel Strategy 22.3.5. Egalet Corporation 22.3.5.1. Overview 22.3.5.2. Product Portfolio 22.3.5.3. Profitability by Market Segments (Product/Channel/Region) 22.3.5.4. Sales Footprint 22.3.5.5. Strategy Overview 22.3.5.5.1. Marketing Strategy 22.3.5.5.2. Product Strategy 22.3.5.5.3. Channel Strategy 22.3.6. Eisai Co. Ltd. 22.3.6.1. Overview 22.3.6.2. Product Portfolio 22.3.6.3. Profitability by Market Segments (Product/Channel/Region) 22.3.6.4. Sales Footprint 22.3.6.5. Strategy Overview 22.3.6.5.1. Marketing Strategy 22.3.6.5.2. Product Strategy 22.3.6.5.3. Channel Strategy 22.3.7. Eli Lilly and Company 22.3.7.1. Overview 22.3.7.2. Product Portfolio 22.3.7.3. Profitability by Market Segments (Product/Channel/Region) 22.3.7.4. Sales Footprint 22.3.7.5. Strategy Overview 22.3.7.5.1. Marketing Strategy 22.3.7.5.2. Product Strategy 22.3.7.5.3. Channel Strategy 22.3.8. F. Hoffmann-La Roche Ltd. 22.3.8.1. Overview 22.3.8.2. Product Portfolio 22.3.8.3. Profitability by Market Segments (Product/Channel/Region) 22.3.8.4. Sales Footprint 22.3.8.5. Strategy Overview 22.3.8.5.1. Marketing Strategy 22.3.8.5.2. Product Strategy 22.3.8.5.3. Channel Strategy 23. Assumptions and Acronyms Used 24. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Osteoporosis Therapeutics Market Volume (‘000 Units) Analysis and Opportunity Assessment 2017–2026, By Drug Class
Table 02: Global Osteoporosis Therapeutics Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2026, By Drug Class
Table 03: Global Osteoporosis Therapeutics Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2026, By Route of Administration
Table 04: Global Osteoporosis Therapeutics Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2026, By Region
Table 05: North America Osteoporosis Therapeutics Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022–2026, By Country
Table 06: North America Osteoporosis Therapeutics Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2026, By Drug Class
Table 07: North America Osteoporosis Therapeutics Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2026, By Route of Administration
Table 08: Latin America Osteoporosis Therapeutics Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022–2026, By Country
Table 09: Latin America Osteoporosis Therapeutics Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2026, By Drug Class
Table 10: Latin America Osteoporosis Therapeutics Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2026, By Route of Administration
Table 11: Europe Osteoporosis Therapeutics Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022–2026, By Country
Table 12: Europe Osteoporosis Therapeutics Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2026, By Drug Class
Table 13: Europe Osteoporosis Therapeutics Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2026, By Route of Administration
Table 14: South Asia Osteoporosis Therapeutics Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022–2026, By Country
Table 15: South Asia Osteoporosis Therapeutics Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2026, By Drug Class
Table 16: South Asia Osteoporosis Therapeutics Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2026, By Route of Administration
Table 17: East Asia Osteoporosis Therapeutics Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022–2026, By Country
Table 18: East Asia Osteoporosis Therapeutics Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2026, By Drug Class
Table 19: East Asia Osteoporosis Therapeutics Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2026, By Route of Administration
Table 20: Oceania Osteoporosis Therapeutics Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022–2026, By Country
Table 21: Oceania Osteoporosis Therapeutics Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2026, By Drug Class
Table 22: Oceania Osteoporosis Therapeutics Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2026, By Route of Administration
Table 23: Middle East and Africa Osteoporosis Therapeutics Market Value (US$ Mn) Analysis 2017-2021 and Forecast 2022–2026, By Country
Table 24: Middle East and Africa Osteoporosis Therapeutics Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2026, By Drug Class
Table 25: Middle East and Africa Osteoporosis Therapeutics Market Value (US$ Mn) Analysis and Opportunity Assessment 2017–2026, By Route of Administration
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Osteoporosis Therapeutics Market Volume (in 000' Units) Analysis, 2017-2021
Figure 02: Global Osteoporosis Therapeutics Market Volume Forecast (in 000' Units), 2022-2026
Figure 03: Osteoporosis Therapeutics Pricing Analysis (US$) Per Product, By Region, 2021
Figure 04: Osteoporosis Therapeutics Pricing Analysis (US$) Per Product, By Region, 2021
Figure 05: Global Osteoporosis Therapeutics Market Value Analysis (US$ Mn), 2017-2021
Figure 06: Global Osteoporosis Therapeutics Market Value Forecast (US$ Mn), 2022-2026
Figure 07: Global Osteoporosis Therapeutics Market Absolute $ Opportunity, 2022-2026
Figure 08: Global Osteoporosis Therapeutics Market Share Analysis (%), By Drug Class, 2022-2026
Figure 09: Global Osteoporosis Therapeutics Market Y-o-Y Analysis (%), By Drug Class, 2022-2026
Figure 10: Global Osteoporosis Therapeutics Market Attractiveness Analysis by Drug Class, 2022-2026
Figure 11: Global Osteoporosis Therapeutics Market Share Analysis (%), By Route of Administration, 2022-2026
Figure 12: Global Osteoporosis Therapeutics Market Y-o-Y Analysis (%), By Route of Administration, 2022-2026
Figure 13: Global Osteoporosis Therapeutics Market Attractiveness Analysis by Route of Administration, 2022-2026
Figure 14: Global Osteoporosis Therapeutics Market Share Analysis (%), By Region, 2022-2026
Figure 15: Global Osteoporosis Therapeutics Market Y-o-Y Analysis (%), By Region, 2022-2026
Figure 16: Global Osteoporosis Therapeutics Market Attractiveness Analysis by Region, 2022-2026
Figure 17: North America Osteoporosis Therapeutics Market Value Share, By Drug Class, 2022 (E)
Figure 18: North America Osteoporosis Therapeutics Market Value Share, By Route of Administration, 2022 (E)
Figure 19: North America Osteoporosis Therapeutics Market Value Share, By Country, 2022 (E)
Figure 20: North America Osteoporosis Therapeutics Market Value Analysis (US$ Mn), 2017-2021
Figure 21: North America Osteoporosis Therapeutics Market Value Forecast (US$ Mn), 2022-2026
Figure 22: North America Osteoporosis Therapeutics Market Attractiveness Analysis by Drug Class, 2022-2026
Figure 23: North America Osteoporosis Therapeutics Market Attractiveness Analysis by Route of Administration, 2022-2026
Figure 24: North America Osteoporosis Therapeutics Market Attractiveness Analysis by Country, 2022-2026
Figure 25: Latin America Osteoporosis Therapeutics Market Value Share, By Drug Class, 2022 (E)
Figure 26: Latin America Osteoporosis Therapeutics Market Value Share, By Route of Administration, 2022 (E)
Figure 27: Latin America Osteoporosis Therapeutics Market Value Share, By Country, 2022 (E)
Figure 28: Latin America Osteoporosis Therapeutics Market Value Analysis (US$ Mn), 2017-2021
Figure 29: Latin America Osteoporosis Therapeutics Market Value Forecast (US$ Mn), 2022-2026
Figure 30: Latin America Osteoporosis Therapeutics Market Attractiveness Analysis by Drug Class, 2022-2026
Figure 31: Latin America Osteoporosis Therapeutics Market Attractiveness Analysis by Route of Administration, 2022-2026
Figure 32: Latin America Osteoporosis Therapeutics Market Attractiveness Analysis by Country, 2022-2026
Figure 33: Europe Osteoporosis Therapeutics Market Value Share, By Drug Class, 2022 (E)
Figure 34: Europe Osteoporosis Therapeutics Market Value Share, By Route of Administration, 2022 (E)
Figure 35: Europe Osteoporosis Therapeutics Market Value Share, By Country, 2022 (E)
Figure 36: Europe Osteoporosis Therapeutics Market Value Analysis (US$ Mn), 2017-2021
Figure 37: Europe Osteoporosis Therapeutics Market Value Forecast (US$ Mn), 2022-2026
Figure 38: Europe Osteoporosis Therapeutics Market Attractiveness Analysis by Drug Class, 2022-2026
Figure 39: Europe Osteoporosis Therapeutics Market Attractiveness Analysis by Route of Administration, 2022-2026
Figure 40: Europe Osteoporosis Therapeutics Market Attractiveness Analysis by Country, 2022-2026
Figure 41: South Asia Osteoporosis Therapeutics Market Value Share, By Drug Class, 2022 (E)
Figure 42: South Asia Osteoporosis Therapeutics Market Value Share, By Route of Administration, 2022 (E)
Figure 43: South Asia Osteoporosis Therapeutics Market Value Share, By Country, 2022 (E)
Figure 44: South Asia Osteoporosis Therapeutics Market Value Analysis (US$ Mn), 2017-2021
Figure 45: South Asia Osteoporosis Therapeutics Market Value Forecast (US$ Mn), 2022-2026
Figure 46: South Asia Osteoporosis Therapeutics Market Attractiveness Analysis by Drug Class, 2022-2026
Figure 47: South Asia Osteoporosis Therapeutics Market Attractiveness Analysis by Route of Administration, 2022-2026
Figure 48: South Asia Osteoporosis Therapeutics Market Attractiveness Analysis by Country, 2022-2026
Figure 49: East Asia Osteoporosis Therapeutics Market Value Share, By Drug Class, 2022 (E)
Figure 50: East Asia Osteoporosis Therapeutics Market Value Share, By Route of Administration, 2022 (E)
Figure 51: East Asia Osteoporosis Therapeutics Market Value Share, By Country, 2022 (E)
Figure 52: East Asia Osteoporosis Therapeutics Market Value Analysis (US$ Mn), 2017-2021
Figure 53: East Asia Osteoporosis Therapeutics Market Value Forecast (US$ Mn), 2022-2026
Figure 54: East Asia Osteoporosis Therapeutics Market Attractiveness Analysis by Drug Class, 2022-2026
Figure 55: East Asia Osteoporosis Therapeutics Market Attractiveness Analysis by Route of Administration, 2022-2026
Figure 56: East Asia Osteoporosis Therapeutics Market Attractiveness Analysis by Country, 2022-2026
Figure 57: Oceania Osteoporosis Therapeutics Market Value Share, By Drug Class, 2022 (E)
Figure 58: Oceania Osteoporosis Therapeutics Market Value Share, By Route of Administration, 2022 (E)
Figure 59: Oceania Osteoporosis Therapeutics Market Value Share, By Country, 2022 (E)
Figure 60: Oceania Osteoporosis Therapeutics Market Value Analysis (US$ Mn), 2017-2021
Figure 61: Oceania Osteoporosis Therapeutics Market Value Forecast (US$ Mn), 2022-2026
Figure 62: Oceania Osteoporosis Therapeutics Market Attractiveness Analysis by Drug Class, 2022-2026
Figure 63: Oceania Osteoporosis Therapeutics Market Attractiveness Analysis by Route of Administration, 2022-2026
Figure 64: Oceania Osteoporosis Therapeutics Market Attractiveness Analysis by Country, 2022-2026
Figure 65: Middle East and Africa Osteoporosis Therapeutics Market Value Share, By Drug Class, 2022 (E)
Figure 66: Middle East and Africa Osteoporosis Therapeutics Market Value Share, By Route of Administration, 2022 (E)
Figure 67: Middle East and Africa Osteoporosis Therapeutics Market Value Share, By Country, 2022 (E)
Figure 68: Middle East and Africa Osteoporosis Therapeutics Market Value Analysis (US$ Mn), 2017-2021
Figure 69: Middle East and Africa Osteoporosis Therapeutics Market Value Forecast (US$ Mn), 2022-2026
Figure 70: Middle East and Africa Osteoporosis Therapeutics Market Attractiveness Analysis by Drug Class, 2022-2026
Figure 71: Middle East and Africa Osteoporosis Therapeutics Market Attractiveness Analysis by Route of Administration, 2022-2026
Figure 72: Middle East and Africa Osteoporosis Therapeutics Market Attractiveness Analysis by Country, 2022-2026
Figure 73: U. S. Osteoporosis Therapeutics Market Value Analysis (US$ Mn), 2022 & 2026
Figure 74: U. S. Osteoporosis Therapeutics Market Value Share, By Drug Class, 2022 (E)
Figure 75: U. S. Osteoporosis Therapeutics Market Value Share, By Route of Administration, 2022 (E)
Figure 76: Canada Osteoporosis Therapeutics Market Value Analysis (US$ Mn), 2022 & 2026
Figure 77: Canada Osteoporosis Therapeutics Market Value Share, By Drug Class, 2022 (E)
Figure 78: Canada Osteoporosis Therapeutics Market Value Share, By Route of Administration, 2022 (E)
Figure 79: Mexico Osteoporosis Therapeutics Market Value Analysis (US$ Mn), 2022 & 2026
Figure 80: Mexico Osteoporosis Therapeutics Market Value Share, By Drug Class, 2022 (E)
Figure 81: Mexico Osteoporosis Therapeutics Market Value Share, By Route of Administration, 2022 (E)
Figure 82: Brazil Osteoporosis Therapeutics Market Value Analysis (US$ Mn), 2022 & 2026
Figure 83: Brazil Osteoporosis Therapeutics Market Value Share, By Drug Class, 2022 (E)
Figure 84: Brazil Osteoporosis Therapeutics Market Value Share, By Route of Administration, 2022 (E)
Figure 85: U. K. Osteoporosis Therapeutics Market Value Analysis (US$ Mn), 2022 & 2026
Figure 86: U. K. Osteoporosis Therapeutics Market Value Share, By Drug Class, 2022 (E)
Figure 87: U. K. Osteoporosis Therapeutics Market Value Share, By Route of Administration, 2022 (E)
Figure 88: Germany Osteoporosis Therapeutics Market Value Analysis (US$ Mn), 2022 & 2026
Figure 89: Germany Osteoporosis Therapeutics Market Value Share, By Drug Class, 2022 (E)
Figure 90: Germany Osteoporosis Therapeutics Market Value Share, By Route of Administration, 2022 (E)
Figure 91: France Osteoporosis Therapeutics Market Value Analysis (US$ Mn), 2022 & 2026
Figure 92: France Osteoporosis Therapeutics Market Value Share, By Drug Class, 2022 (E)
Figure 93: France Osteoporosis Therapeutics Market Value Share, By Route of Administration, 2022 (E)
Figure 94: Italy Osteoporosis Therapeutics Market Value Analysis (US$ Mn), 2022 & 2026
Figure 95: Italy Osteoporosis Therapeutics Market Value Share, By Drug Class, 2022 (E)
Figure 96: Italy Osteoporosis Therapeutics Market Value Share, By Route of Administration, 2022 (E)
Figure 97: Spain Osteoporosis Therapeutics Market Value Analysis (US$ Mn), 2022 & 2026
Figure 98: Spain Osteoporosis Therapeutics Market Value Share, By Drug Class, 2022 (E)
Figure 99: Spain Osteoporosis Therapeutics Market Value Share, By Route of Administration, 2022 (E)
Figure 100: Russia Osteoporosis Therapeutics Market Value Analysis (US$ Mn), 2022 & 2026
Figure 101: Russia Osteoporosis Therapeutics Market Value Share, By Drug Class, 2022 (E)
Figure 102: Russia Osteoporosis Therapeutics Market Value Share, By Route of Administration, 2022 (E)
Figure 103: China Osteoporosis Therapeutics Market Value Analysis (US$ Mn), 2022 & 2026
Figure 104: China Osteoporosis Therapeutics Market Value Share, By Drug Class, 2022 (E)
Figure 105: China Osteoporosis Therapeutics Market Value Share, By Route of Administration, 2022 (E)
Figure 106: Japan Osteoporosis Therapeutics Market Value Analysis (US$ Mn), 2022 & 2026
Figure 107: Japan Osteoporosis Therapeutics Market Value Share, By Drug Class, 2022 (E)
Figure 108: Japan Osteoporosis Therapeutics Market Value Share, By Route of Administration, 2022 (E)
Figure 109: South Korea Osteoporosis Therapeutics Market Value Analysis (US$ Mn), 2022 & 2026
Figure 110: South Korea Osteoporosis Therapeutics Market Value Share, By Drug Class, 2022 (E)
Figure 111: South Korea Osteoporosis Therapeutics Market Value Share, By Route of Administration, 2022 (E)
Figure 112: India Osteoporosis Therapeutics Market Value Analysis (US$ Mn), 2022 & 2026
Figure 113: India Osteoporosis Therapeutics Market Value Share, By Drug Class, 2022 (E)
Figure 114: India Osteoporosis Therapeutics Market Value Share, By Route of Administration, 2022 (E)
Figure 115: ASEAN Osteoporosis Therapeutics Market Value Analysis (US$ Mn), 2022 & 2026
Figure 116: ASEAN Osteoporosis Therapeutics Market Value Share, By Drug Class, 2022 (E)
Figure 117: ASEAN Osteoporosis Therapeutics Market Value Share, By Route of Administration, 2022 (E)
Figure 118: Australia Osteoporosis Therapeutics Market Value Analysis (US$ Mn), 2022 & 2026
Figure 119: Australia Osteoporosis Therapeutics Market Value Share, By Drug Class, 2022 (E)
Figure 120: Australia Osteoporosis Therapeutics Market Value Share, By Route of Administration, 2022 (E)
Figure 121: New Zealand Osteoporosis Therapeutics Market Value Analysis (US$ Mn), 2022 & 2026
Figure 122: New Zealand Osteoporosis Therapeutics Market Value Share, By Drug Class, 2022 (E)
Figure 123: New Zealand Osteoporosis Therapeutics Market Value Share, By Route of Administration, 2022 (E)
Figure 124: GCC Countries Osteoporosis Therapeutics Market Value Analysis (US$ Mn), 2022 & 2026
Figure 125: GCC Countries Osteoporosis Therapeutics Market Value Share, By Drug Class, 2022 (E)
Figure 126: GCC Countries Osteoporosis Therapeutics Market Value Share, By Route of Administration, 2022 (E)
Figure 127: Turkey Osteoporosis Therapeutics Market Value Analysis (US$ Mn), 2022 & 2026
Figure 128: Turkey Osteoporosis Therapeutics Market Value Share, By Drug Class, 2022 (E)
Figure 129: Turkey Osteoporosis Therapeutics Market Value Share, By Route of Administration, 2022 (E)
Figure 130: South Africa Osteoporosis Therapeutics Market Value Analysis (US$ Mn), 2022 & 2026
Figure 131: South Africa Osteoporosis Therapeutics Market Value Share, By Drug Class, 2022 (E)
Figure 132: South Africa Osteoporosis Therapeutics Market Value Share, By Route of Administration, 2022 (E)
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What is the osteoporosis therapeutics market value at present?
The global osteoporosis therapeutics market is valued at US$ 12.7 Bn at present.
How big will the osteoporosis therapeutics market be by 2026?
The global market for osteoporosis therapeutics is slated to reach a valuation of US$ 14.2 Bn by the end of 2026.
How will demand for osteoporosis therapeutic drugs rise over the forecast period?
Consumption of osteoporosis therapeutic drugs is projected to expand at a sluggish CAGR 2.9% from 2022 to 2026.
Who are the key osteoporosis therapeutics market players mentioned in this research?
Key osteoporosis therapeutic drug manufacturers are Allergan Plc., Amgen Inc., Chugai Pharmaceutical, Daiichi Sankyo Co. Ltd., Egalet Corporation, and Eisai Co. Ltd.
What market share is held by the U.S?
The U.S. currently accounts for 41% of the global osteoporosis therapeutics market share.
At what rate will the China osteoporosis therapeutics market expand?
The China osteoporosis therapeutics market is anticipated to rise at a CAGR of 5.4% from 2022 to 2026.
Osteoporosis Therapeutics Market